Nuvation Bio warrants delisted from NYSE

Nuvation Bio Inc. has had its redeemable warrants removed from listing and registration on the New York Stock Exchange.

Rhea-AI Filing Summary

Nuvation Bio Inc. has had its redeemable warrants removed from listing and registration on the New York Stock Exchange. These warrants were exercisable on a one-for-one basis for shares of Class A common stock at an exercise price of $11.50 per share.

The New York Stock Exchange filed this notification, certifying that it followed its own rules to strike this class of securities from listing and registration. The filing also states that Nuvation Bio complied with the Exchange’s rules and the requirements governing voluntary withdrawal of this warrant class from the Exchange.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Nuvation Bio Inc. (NUVB) file regarding its warrants?

Nuvation Bio Inc. had its redeemable warrants delisted from the NYSE. A Form 25 was filed by the New York Stock Exchange to remove this class of warrants from listing and registration after both the Exchange and the company complied with applicable rules.

Which Nuvation Bio (NUVB) securities are affected by this Form 25?

The affected securities are Nuvation Bio’s redeemable warrants. Each whole warrant was exercisable for one share of Class A common stock at an exercise price of $11.50 per share and has now been removed from NYSE listing and registration.

Who initiated the delisting of Nuvation Bio (NUVB) warrants?

The New York Stock Exchange filed the notification to delist the warrants. The filing states the Exchange followed its own rules to strike the warrant class, and that Nuvation Bio satisfied Exchange requirements for voluntary withdrawal of these securities.

What regulatory rule governs Nuvation Bio’s (NUVB) warrant delisting?

The delisting is governed by 17 CFR 240.12d2-2. The filing cites subsections (a), (b), and (c), noting that both the Exchange and Nuvation Bio met the conditions for removal of the warrant class from listing and registration on the NYSE.

Does the Form 25 affect Nuvation Bio’s Class A common stock listing?

The document only addresses redeemable warrants, not common stock. It specifies removal of the warrant class from NYSE listing and registration, without mentioning any change to the listing status of Nuvation Bio’s Class A common shares.

Who signed the NYSE notification for Nuvation Bio (NUVB) warrant delisting?

The notification was signed on behalf of the New York Stock Exchange by Tyler Mastronardi. He is identified as an Analyst in Market Watch, acting as a duly authorized person for purposes of the Form 25 certification.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/10/2026 - 02:20 PM Learn about SEC filing dates

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-39351

Issuer:	Nuvation Bio Inc.
Exchange:	NEW YORK STOCK EXCHANGE LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	1500 BROADWAY, SUITE 1401
	New York	NEW YORK	10036
Telephone number:

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Redeemable warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, NEW YORK STOCK EXCHANGE LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2026-02-10	By	Tyler Mastronardi		Analyst, Market Watch
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.